Premium
Short course of R‐HyperCVAD/MTX / ARA‐C followed by ASCT as first‐line therapy in mantle cell lymphoma patients prolongs progression‐free survival to more than 9 years
Author(s) -
Andrade Campos M.,
Mercadal S.,
Domingo Domenech E.,
Paredes V.,
Aguilera C.,
Oliveira A.,
Banda E.,
Climent F.,
Parody R.,
Fernandez de Sevilla A.,
Sureda A.,
Gonzalez Barca E.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2439_113
Subject(s) - medicine , mantle cell lymphoma , autologous stem cell transplantation , cytarabine , retrospective cohort study , surgery , gastroenterology , oncology , lymphoma , chemotherapy